Today announced a solution for exon analysis predicated on SurePrint G3 Exon Microarrays.

This new program, available in mid-November, enables experts to examine alternately expressed exons according to lately updated content, providing a worldwide picture of RNA expression.D., Agilent product supervisor, Gene Expression. In December we introduced the reduced Input Quick Amp labeling kit, which requires only 10 nanograms of total RNA. Last May, we launched the third-era SurePrint G3 Gene Expression microarrays, such as both coding and non-coding RNA targets on a single array. Related StoriesSausages With Antioxidants From Berries TO AVOID CancerFDA grants accelerated authorization for Tagrisso to take care of patients with advanced NSCLCNew RNA check of blood platelets may be used to detect location of cancerAgilent can be leveraging the functionality and density of the SurePrint platform to provide a full-exon option to help researchers discover the relationships between around 30,000 genes and more than 100,000 proteins.At 6 and 12 months the individuals that remained in each group had been assessed for their cognitive status and neuropsychiatric symptoms. The experts found that there have been no differences between the two groups with regards to cognitive decline. They also found no overall differences between your two groups in the noticeable change in the amount of neuropsychiatric symptoms. Patients with serious neuropsychiatric problems at the outset of the trial may have had some benefit from continued neuroleptic therapy, but this difference was not significant statistically. Related StoriesHealth Education England launches Dementia Primary Skills Education and Teaching FrameworkLewy Body Composite Risk Rating detects LBD and Parkinson's disease dementia in 3 minutesMayo Clinic's Florida campus awarded NIH grant to identify vascular risk factors in aging and dementiaAlmost all older dementia sufferers could have some neuropsychiatric symptoms.